Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 3,262 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Milk and/or Peanut Allergy
Interventions: Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk); Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo, AMX0035; Other · Drug
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 28
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 23 more

Conditions: Enterovirus Infection
Interventions: Placebo, Pleconaril; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 0 Days to 15 Days
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Breast Cancer
Interventions: Gemcitabine, Sorafenib, Placebo, Capecitabine; Drug
Lead sponsor: Accelerated Community Oncology Research Network; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 44
States / cities: Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more

Conditions: Healthy
Interventions: BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Headache, Migraine, Migraine, Migraine Disorders, Headache
Interventions: Cognitive Behavioral Therapy (CBT), Placebo, Amitriptyline, Biofeedback-Assisted Relaxation Training (BART), Cognitive Reappraisal Training (CR); Behavioral · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 17 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cardiovascular Disease, Vitamin D Deficiency
Interventions: Vitamin D3, Placebo; Dietary Supplement
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Conditions: CRC (Colorectal Cancer)
Interventions: INCA33890, Placebo, Bevacizumab, FOLFOX; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 78
States / cities: Mobile, Alabama • Tucson, Arizona • Fountain Valley, California + 65 more

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 79
States / cities: Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: San Diego, California • Santa Monica, California • Fort Myers, Florida + 15 more

Conditions: Cutaneous T-Cell Lymphoma
Interventions: SGX301 (synthetic hypericin), Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more

Conditions: Oropharynx Cancer
Interventions: Minocycline, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
Interventions: Brentuximab Vedotin, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more

Conditions: Diabetes, Effects of Liraglutide Administration on Brain Activity, Weight Loss, Hunger
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 40
States / cities: Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more

Conditions: Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
Interventions: VIS649, Placebo; Biological
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Overweight, Healthy Subjects
Interventions: SAR441255, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Renal Dialysis, Kidney Failure, Chronic
Interventions: MK-2060, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Postoperative Pain, Postoperative Nausea and Vomiting
Interventions: Ropivacaine, Placebo, Transversus Abdominis Plane Block; Drug · Other · Procedure
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Influenza
Interventions: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV), H3N2v inactivated subvirion influenza vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 26 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Heavy Drinking, HIV, Alcohol Dependence
Interventions: Topiramate, Medical Management, Placebo; Drug · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Interventions: Nintedanib and AML induction; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: New Haven, Connecticut • Nashville, Tennessee

Conditions: Healthy Adult
Interventions: L-histidine, Monosodium glutamate (MSG), Sodium chloride (NaCl); Dietary Supplement
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ovarian Neoplasms, Peritoneal Neoplasms
Interventions: Placebo, Paclitaxel, BIBF 1120, Carboplatin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 33
States / cities: Tucson, Arizona • Long Beach, California • Santa Rosa, California + 28 more

Search by objective public record fields.

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

Pleconaril Enteroviral Sepsis Syndrome

1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Mind and Body Approaches to Pain Reduction in Youth With Migraine

Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.

Brentuximab Vedotin for Systemic Sclerosis

Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

First in Human Study to Assess Safety of VIS649 in Healthy Subjects

First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

Intraoperative Transversus Abdominis Plane Block for Gynecologic Surgery (GYNTAP)

Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease

Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

Effect of Monosodium Glutamate on Microbiome-Derived Imidazole Propionate Production in Healthy Volunteers

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer